Promoter Hypermethylation of ATG16L2, TFAP2A, EBF2, Calcitonin, ABL1 Kinase Domain T315I Mutation Association with Imatinib Therapy Resistance and Median Survival in CML Patients of North-East India

Background and Objectives: Chronic myeloid leukemia (CML) initiation progression is regulated by epigenetic genetic alterations. Imatinib therapy resistance in CML patients important clinical issue. To understand association of kinase domain mutation promoter hypermethylation genes with imatinib hold significance North-East India. This study a hospital based cross sectional study. Methods: A total Sixty three (n=63) undergone mesylate were enrolled for the ABL T315I was analyzed Allele specific- PCR (AS-PCR) confirmed sequencing. Promoter Methylation specific (MS-PCR). The Chi square test Fisher exact used SPSS ver19. Results: Tyrosine Kinase found 30.1% (19/63). Calcitonin, ATG16L2, TFAP2A, EBF2 gene detected 42.9% (n=27), 28.6% (n=18), 38.1% (n=24), 27% (n= 17) respectively. Median relapse free survival 21 months statistically significant without compared to who has 12 median (p=0.005). 19 also (12 months) (p=0.026). Interpretation Conclusions: We conclude that among resistant North- East India harbouring ABL1 have significantly lower survival.